Author's response to reviews

Title: A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study.

Authors:

  Joanne Smith (SealJD@cf.ac.uk)
  Jessica Baillie (BaillieJ4@cf.ac.uk)
  Trevor Baglin (trevor.baglin@addenbrookes.nhs.uk)
  Gareth O Griffiths (GriffithsG@cf.ac.uk)
  Angela Casbard (CasbardAC@cf.ac.uk)
  David Cohen (david.cohen@southwales.ac.uk)
  David A Fitzmaurice (d.a.fitzmaurice@bham.ac.uk)
  Kerenza Hood (HoodK1@cf.ac.uk)
  Peter Rose (Peter_Rose@swft.nhs.uk)
  Alexander T Cohen (alexander.cohen@kcl.ac.uk)
  Miriam Johnson (miriam.johnson@hyms.ac.uk)
  Anthony Maraveyas (anthony.maraveyas@hey.nhs.uk)
  John Bell (j.bell904@btinternet.com)
  Harold Toone (safeman5@aol.com)
  Annmarie Nelson (NelsonA9@cf.ac.uk)
  Simon I Noble (Simon.Noble@wales.nhs.uk)

Version: 3
Date: 19 March 2014

Author's response to reviews: see over
Dear Jessie,

RE: MS 1038374439116530
“A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study.”

Thank you very much for your email. Please see attached the revised manuscript, where the title has been altered in line with the journal requirements and the authorship contributions have been clarified. These changes are highlighted in red.

If you require any additional information please do not hesitate to contact me.

Kind regards,

Dr Jessica Baillie